您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Atazanavir-d6
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Atazanavir-d6
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Atazanavir-d6图片
CAS NO:1092540-50-5
包装:1mg
市场价:3009元

产品介绍
An internal standard for the quantification of atazanavir
Cas No.1092540-50-5
别名阿扎那韦D6,BMS-232632-d6
Canonical SMILESO=C(N[C@@H](C(C)(C)C)C(N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC2=CC=C(C3=NC=CC=C3)C=C2)NC([C@@H](NC(OC([2H])([2H])[2H])=O)C(C)(C)C)=O)=O)OC([2H])([2H])[2H]
分子式C38H46D6N6O7
分子量710.9
溶解度Ethanol: Slightly Soluble,Methanol: Slightly Soluble
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Atazanavir-d6is intended for use as an internal standard for the quantification of atazanavir by GC- or LC-MS. Atazanavir is an azapeptide inhibitor of HIV-1 protease (Ki= 2.66 nM).1It has antiviral activity against a variety of HIV-1 strains in several cell types with EC50values ranging from 2.62 to 5.28 nM. Atazanavir exhibits a minor synergistic effect when used in combination with the reverse transcriptase inhibitor zidovudine in HIV-1-infected human peripheral blood mononuclear cells (PBMCs) and an additive effect when used in combination with several additional reverse transcriptase or HIV-1 protease inhibitors. Atazanavir also inhibits UDP-glucuronyltransferase 1A1 (UGT1A1), which is involved in bilirubin clearance.2Formulations containing atazanavir have been used in combination therapy for the treatment of HIV-1 infection.

1.Robinson, B.S., Riccardi, K.A., Gong, Y.F., et al.BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agentsAntimicrobial Agents and Chemotherapy44(8)2093-2099(2000) 2.Michaud, V., Bar-Magen, T., Turgeon, J., et al.The dual role of pharmacogenetics in HIV treatment: Mutations and polymorphisms regulating antiretroviral drug resistance and dispositionPharmacological Reviews64(3)803-833(2012)